- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 303982, 11 pages
A Machine-Learned Predictor of Colonic Polyps Based on Urinary Metabolomics
1Department of Computing Science, University of Alberta, Edmonton, AB, Canada T6G 2E8
2Division of Gastroenterology, Zeidler Ledcor Centre, University of Alberta, Edmonton, AB, Canada T6G 2X8
3Department of Surgery, 2D2.29 WC Mackenzie Health Science Centre, University of Alberta, Edmonton, AB, Canada T6G 2R7
Received 10 July 2013; Revised 29 August 2013; Accepted 8 September 2013
Academic Editor: Yudong Cai
Copyright © 2013 Roman Eisner et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- International Agency for Research on Cancer and World Health Organization, “Estimated cancer Incidence, mortality, prevalence and disability-adjusted life years (DALYs) worldwide,” GLOBOCAN 2008, International Agency for Research on Cancer, Lyon, France, 2008.
- D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, “Global cancer statistics, 2002,” CA: A Cancer Journal for Clinicians, vol. 55, no. 2, pp. 74–108, 2005.
- “Colon and rectal cancer,” National Cancer Institute http://www.cancer.gov/cancertopics/types/colon-and-rectal.
- Canadian Cancer Society's Steering Committee on Cancer Statistics, Canadian Cancer Statistics, Toronto, Canada, 2011.
- D. J. Leddin, R. Enns, R. Hilsden et al., “Canadian Association of Gastroenterology position statement on screening individuals at average risk for developing colorectal cancer: 2010,” Canadian Journal of Gastroenterology, vol. 24, no. 12, pp. 705–714, 2010.
- D. P. Taylor, L. A. Cannon-Albright, C. Sweeney et al., “Comparison of compliance for colorectal cancer screening and surveillance by colonoscopy based on risk,” Genetics in Medicine, vol. 13, no. 8, pp. 737–743, 2011.
- C. K. W. Wong, R. N. Fedorak, C. I. Prosser, M. E. Stewart, S. V. van Zanten, and D. C. Sadowski, “The sensitivity and specificity of guaiac and immunochemical fecal occult blood tests for the detection of advanced colonic adenomas and cancer,” International Journal of Colorectal Disease, vol. 27, no. 12, pp. 1657–1664, 2012.
- J. E. Allison, I. S. Tekawa, L. J. Ransom, and A. L. Adrain, “A comparison of fecal occult-blood tests for colorectal-cancer screening,” The New England Journal of Medicine, vol. 334, no. 3, pp. 155–159, 1996.
- T. F. Imperiale, D. F. Ransohoff, S. H. Itzkowitz, B. A. Turnbull, and M. E. Ross, “Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population,” The New England Journal of Medicine, vol. 351, no. 26, pp. 2704–2714, 2004.
- E. P. Whitlock, J. S. Lin, E. Liles, T. L. Beil, and R. Fu, “Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force,” Annals of Internal Medicine, vol. 149, no. 9, pp. 638–658, 2008.
- J. Maroun, E. Ng, J.-M. Berthelot et al., “Lifetime costs of colon and rectal cancer management in Canada,” Chronic Diseases in Canada, vol. 24, no. 4, pp. 91–101, 2003.
- D. S. Wishart, T. Jewison, A. C. Guo, et al., “HMDB 3.0—the human metabolome database in 2013,” Nucleic Acids Research, vol. 41, pp. D801–D807, 2013.
- A. M. Weljie, J. Newton, P. Mercier, E. Carlson, and C. M. Slupsky, “Targeted pofiling: quantitative analysis of 1H-NMR metabolomics data,” Analytical Chemistry, vol. 78, no. 13, pp. 4430–4442, 2006.
- D. S. Wishart, “Quantitative metabolomics using NMR,” TrAC—Trends in Analytical Chemistry, vol. 27, no. 3, pp. 228–237, 2008.
- R. Eisner, C. Stretch, T. Eastman et al., “Learning to predict cancer-associated skeletal muscle wasting from 1H-NMR profiles of urinary metabolites,” Metabolomics, vol. 7, no. 1, pp. 25–34, 2011.
- C. Stretch, T. Eastman, R. Mandal et al., “Prediction of skeletal muscle and fat mass in patients with advanced cancer using a metabolomic approach,” Journal of Nutrition, vol. 142, no. 1, pp. 14–21, 2012.
- J. Xia, N. Psychogios, N. Young, and D. S. Wishart, “MetaboAnalyst: a web server for metabolomic data analysis and interpretation,” Nucleic Acids Research, vol. 37, no. 2, pp. W652–W660, 2009.
- E. Holmes, P. J. D. Foxall, J. K. Nicholson et al., “Automatic data reduction and pattern recognition methods for analysis of 1H nuclear magnetic resonance spectra of human urine from normal and pathological states,” Analytical Biochemistry, vol. 220, no. 2, pp. 284–296, 1994.
- F. Dieterle, A. Ross, G. Schlotterbeck, and H. Senn, “Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H-NMR metabonomics,” Analytical Chemistry, vol. 78, no. 13, pp. 4281–4290, 2006.
- M. E. Bollard, E. G. Stanley, J. C. Lindon, J. K. Nicholson, and E. Holmes, “NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition,” NMR in Biomedicine, vol. 18, no. 3, pp. 143–162, 2005.
- A. Craig, O. Cloarec, E. Holmes, J. K. Nicholson, and J. C. Lindon, “Scaling and normalization effects in NMR spectroscopic metabonomic data sets,” Analytical Chemistry, vol. 78, no. 7, pp. 2262–2267, 2006.
- J. L. Spratlin, N. J. Serkova, and S. G. Eckhardt, “Clinical applications of metabolomics in oncology: a review,” Clinical Cancer Research, vol. 15, no. 2, pp. 431–440, 2009.
- R. Madsen, T. Lundstedt, and J. Trygg, “Chemometrics in metabolomics—a review in human disease diagnosis,” Analytica Chimica Acta, vol. 659, no. 1-2, pp. 23–33, 2010.
- V. Vapnik, The Nature of Statistical Learning Theory, Springer, New York, NY, USA, 1995.
- E. Frank, M. Hall, G. Holmes, et al., “Weka-A machine learning workbench for data mining,” in Data Mining and Knowledge Discovery Handbook, O. Maimon and L. Rokach, Eds., pp. 1269–1277, Springer, 2nd edition, 2010.
- R. Tibshirani, “Regression shrinkage and selection via the Lasso,” Journal of the Royal Statistical Society B, vol. 58, pp. 267–288, 1996.
- T. Hastie, R. Tibshirani, and J. Friedman, The Elements of Statistical Learning, Springer, New York, NY, USA, 2001.
- F. Provost and T. Fawcett, Analysis and Visualization of Classifier Performance: Comparison under Imprecise Class and Cost Distributions, AAAI Press, 1997.
- M. J. J. Scott, M. Niranjan, and R. W. Prager, “Realisable classifiers: improving operating performance on variable cost problems,” in Proceedings of 9th British Machine Vision Conferenc, pp. 304–315, University of Southampton, Southampton , UK, 1998.
- S. J. Russell and P. Norvig, Artificial Intelligence: A Modern Approach, Prentice Hall, Upper Saddle River, NJ, USA, 2002.
- C. Ding and H. Peng, “Minimum redundancy feature selection from microarray gene expression data,” Journal of Bioinformatics and Computational Biology, vol. 3, no. 2, pp. 185–205, 2005.
- T. Huang, S. Wan, Z. Xu et al., “Analysis and prediction of translation rate based on sequence and functional features of the mRNA,” PLoS ONE, vol. 6, no. 1, Article ID e16036, 2011.
- L. Sun, Y. Yu, T. Huang, et al., “Associations between ionomic profile and metabolic abnormalities in human population,” PLoS ONE, vol. 7, no. 6, Article ID e38845, 2012.
- I. Guyon, J. Weston, S. Barnhill, and V. Vapnik, “Gene selection for cancer classification using support vector machines,” Machine Learning, vol. 46, no. 1–3, pp. 389–422, 2002.
- F. Pesarin, Multivariate Permutation Tests: With Applications in Biostatistics, John Wiley & Sons, Chichester, UK, 2001.
- Y. Qiu, G. Cai, M. Su et al., “Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS,” Journal of Proteome Research, vol. 8, no. 10, pp. 4844–4850, 2009.
- Y. Cheng, G. Xie, T. Chen et al., “Distinct urinary metabolic profile of human colorectal cancer,” Journal of Proteome Research, vol. 11, no. 2, pp. 1354–1363, 2012.
- W. Wang, B. Feng, X. Li et al., “Urinary metabolic profiling of colorectal carcinoma based on online affinity solid phase extraction-high performance liquid chromatography and ultra performance liquid chromatography-mass spectrometry,” Molecular BioSystems, vol. 6, no. 10, pp. 1947–1955, 2010.
- H. Wang, D. E. Schiller, V. Tso, C. Slupsky, C. K. Wong, and R. N. Fedorak, “A novel highly sensitive test for detecting colon cancer using spot urine metabolomics,” Gastroenterology, vol. 140, no. 5, supplement 1, p. S40.
- Y. Qiu, G. Cai, M. Su et al., “Urinary metabonomic study on colorectal cancer,” Journal of Proteome Research, vol. 9, no. 3, pp. 1627–1634, 2010.
- S. Nishiumi, T. Kobayashi, A. Ikeda, et al., “A novel serum metabolomics-based diagnostic approach for colorectal cancer,” PLoS ONE, vol. 7, no. 7, Article ID e40459, 2012.
- M. Mal, P. K. Koh, P. Y. Cheah, and E. C. Y. Chan, “Metabotyping of human colorectal cancer using two-dimensional gas chromatography mass spectrometry,” Analytical and Bioanalytical Chemistry, vol. 403, no. 2, pp. 483–493, 2012.
- Y. Ma, P. Zhang, F. Wang, W. Liu, J. Yang, and H. Qin, “An integrated proteomics and metabolomics approach for defining oncofetal biomarkers in the colorectal cancer,” Annals of Surgery, vol. 255, no. 4, pp. 720–730, 2012.
- H. Wang, V. K. Tso, C. M. Slupsky, and R. N. Fedorak, “Metabolomics and detection of colorectal cancer in humans: a systematic review,” Future Oncology, vol. 6, no. 9, pp. 1395–1406, 2010.
- F. Farshidfar, A. M. Weljie, K. Kopciuk, et al., “Serum metabolomic profile as a means to distinguish stage of colorectal cancer,” Genome Medicine, vol. 4, article 42, 2012.
- Y. Miyagi, M. Higashiyama, A. Gochi et al., “Plasma free amino acid profiling of five types of cancer patients and its application for early detection,” PLoS ONE, vol. 6, no. 9, Article ID e24143, 2011.
- A. Arlt, S. Sebens, S. Krebs, et al., “Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity,” Oncogene, 2012.